OxThera

OxThera is a biopharmaceutical company with products in late-stage clinical development, primarily targeting primary and secondary hyperoxaluria. OxThera's intellectual property includes global patents for the treatment of hyperoxaluria using bacteria and enzymes. Oxabact® has received Orphan Drug designation in Europe and the United States for the treatment of primary hyperoxaluria.